Back to search results

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Abroad (travel likely)RecruitingPHASE1

Conditions

Non-small Cell Lung Cancer (NSCLC) · Anaplastic Lymphoma Kinase (ALK) Positive

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Providence Medical Foundation - Fullerton - Virginia K. Crosson Cancer Center, Fullerton, California, United States

  • University of California - Irvine, Orange, California, United States

  • Emory Winship Cancer Institute, Atlanta, Georgia, United States

  • OSF Health Care, Peoria, Illinois, United States

  • University of Michigan Health Systems, Ann Arbor, Michigan, United States

  • Washington University School of Medicine, St Louis, Missouri, United States

  • Hackensack University Medical Center, Hackensack, New Jersey, United States

  • UT Southwestern Medical Center at Dallas, Dallas, Texas, United States

  • Virginia Cancer Specialists PC, Fairfax, Virginia, United States

  • Site FR33008, Saint-Herblain, France

  • Site FR33005, Toulouse, France

  • Site FR33001, Villejuif, France

  • Site ES34017, Barcelona, Spain

  • Site ES34006, Madrid, Spain

  • Site ES34011, Madrid, Spain

  • Site ES34008, Málaga, Spain

Study leads

  • Medical Monitor

    Study Director

    Astellas Pharma Global Development, Inc.

View source on ClinicalTrials.gov(opens in a new tab)